Allyx Therapeutics
Protecting Synapses and Reversing Neurodegeneration
New Haven, United States
5 employees
Series Unknown
Total: $10.12M
Biotechnology, Health Care +1
General Information
Get notified when Allyx Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Allyx Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Allyx Therapeutics
Taxonomy: Allyx Therapeutics, clinical stage, neurodegeneration, Alzheimer's disease, Parkinson's disease, disease modifying therapies, synapse dysfunction, small molecule, oral drug, cognition preservation, neurological disorders, clinical trials, drug development
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | - | 09 Feb 2023 | |
| Series A | •••••• | 5 |
|
01 Jun 2021 |
| Venture Round | •••••• | 1 |
|
01 Jan 2021 |
| Convertible Note | •••••• | 1 |
|
03 Apr 2019 |
Allyx Therapeutics Alternatives & Competitors
Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegene...
Empowering medical advancements through regenerative medicine and organoid technology for precise di...
Transforming diabetic eye disease with an oral treatment
FAQ About Allyx Therapeutics
Don't just browse. Track.
Signal Tracker monitors Allyx Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.